Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The latest recommendations from the American Diabetes Association and the European Association for the Study of Diabetes prioritize the use of drugs with proven cardiovascular (CV) benefit in patients with established CV disease. Especially among the glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RA) class, results of cardiovascular outcomes trials (CVOT) have been heterogeneous. Baseline characteristics of the population, study design, drugs in the control arm, modifications of CV risk factors, including glycemic control, reduction of hypoglycemia, and the GLP-1RA direct effects on CV cells and tissues, were considered. Ultimately, the time of exposure to the GLP-1RA appears to be the factor most prominently explaining trial heterogeneity. Thus, the CV benefit should be regarded as a class effect of GLP-1RA, as largely similar results are seen for drugs sharing a common mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30194-9 · Cited by 287
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Edelberg, J. M., Goodman, S. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.039 · Cited by 173
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Verma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., Nauck, M. A., Pratley, R. E., Zinman, B., Ørsted, D. D., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034516 · Cited by 127
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93
Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76
Oral semaglutide for the treatment of type 2 diabetes
Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1552258 · Cited by 44
Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.036862 · Cited by 35
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Research works printed but not linked: 30
- Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N. Engl. J. Med., 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 10.1056/NEJMoa1901118 · DOI · Paper page
- Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N. Engl. J. Med., 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page
- American Diabetes Association, 2019, Standards of medical care in diabetes – 2019, Diabetes Care, 42, S187
- Lim, 2018, Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns, Trends Endocrinol. Metab., 29, 238, 10.1016/j.tem.2018.01.011 · DOI
- Ryder, 2017, Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?, Br. J. Diabetes, 17, 131, 10.15277/bjd.2017.147 · DOI
- Li, 2018, Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect?, Curr. Cardiol. Rep., 20, 113, 10.1007/s11886-018-1051-2 · DOI
- Bethel, 2018, Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis, Lancet Diabetes Endocrinol., 6, 105, 10.1016/S2213-8587(17)30412-6 · DOI · Paper page
- Gerstein, 2018, Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide, Diabetes Obes. Metab., 20, 42, 10.1111/dom.13028 · DOI · Paper page
- Bain, 2018, Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial, Diabetes Obes. Metab., 21, 499, 10.1111/dom.13553 · DOI · Paper page
- Svanström, 2018, Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden, Lancet Diabetes Endocrinol., 7, 106, 10.1016/S2213-8587(18)30320-6 · DOI · Paper page
- Boyle, 2018, Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review, Clin. Sci., 132, 1699, 10.1042/CS20171299 · DOI · Paper page
- Frank, 2013, Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes, J. Pharm. Drug Deliv. Res., 50, 886
- Action to Control Cardiovascular Risk in Diabetes Study Group, 2008, Effect of intensive glucose lowering in type 2 diabetes, N. Engl. J. Med., 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
- 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 358, 2560, 10.1056/NEJMoa0802987 · DOI · Paper page
- UK Prospective Diabetes Study Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- Giorgino, 2016, Glucose control and vascular outcomes in type 2 diabetes: is the picture clear?, Diabetes Care, 39, S187, 10.2337/dcS15-3023 · DOI · Paper page
- Dalsgaard, 2018, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons, Diabetes Obes. Metab., 20, 508, 10.1111/dom.13128 · DOI · Paper page
- Taylor, 2018, GLP-1 receptor agonists: differentiation within the class, Lancet Diabetes Endocrinol., 6, 83, 10.1016/S2213-8587(17)30413-8 · DOI
- Zinman, 2018, Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience, Diabetes Care, 41, 1783, 10.2337/dc17-2677 · DOI · Paper page
- Gentilella, 2019, Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?, Diabetes Metab. Res. Rev., 35, 10.1002/dmrr.3070 · DOI · Paper page
- Fineman, 2012, Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes Obes. Metab., 14, 546, 10.1111/j.1463-1326.2012.01561.x · DOI · Paper page
- Sfairopoulos, 2018, Clinical pharmacology of glucagon-like peptide-1 receptor agonists, Hormones, 17, 333, 10.1007/s42000-018-0038-0 · DOI
- Wootten, 2016, The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism, Cell, 165, 1632, 10.1016/j.cell.2016.05.023 · DOI · Paper page
- Drucker, 2018, The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications, Diabetes, 67, 1710, 10.2337/dbi18-0008 · DOI · Paper page
- Leonardini, 2017, GLP-1 receptor activation inhibits palmitate-induced apoptosis via ceramide in human cardiac progenitor cells, J. Clin. Endocrinol. Metab., 102, 4136, 10.1210/jc.2017-00970 · DOI · Paper page
- Laviola, 2012, Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway, Endocrinology, 153, 5770, 10.1210/en.2012-1461 · DOI · Paper page
- Al Batran, 2018, Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism, Peptides, 100, 94, 10.1016/j.peptides.2017.12.005 · DOI
- Bruen, 2017, Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis, Cardiovasc. Diabetol., 16, 153, 10.1186/s12933-017-0626-3 · DOI · Paper page
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
Background
Metadata
- Authors
- Caruso, I., Cignarelli, A., & Giorgino, F.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 30
- Issue
- 9
- Pages
- 578-589
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W2964603908
- Cited by
- 58
- References
- 31
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.